NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Pieris’ Anticalin-Based Drugs Target Cancer, Asthma & Anemia

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company in Boston, is developing Anticalin-based drugs for the treatment of cancer, asthma, anemia and other conditions that show a high unmet medical need. Pieris’ drugs are created in a unique and transformative way, using immuno-oncology multi-specifics tailored for the tumor microenvironment, in addition to an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia.
Pieris’ drugs are created in a unique and transformative way, using immuno-oncology multi-specifics tailored for the tumor microenvironment, in addition to an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia
Through the development of Anticalin proteins, the company produces low-molecular-weight therapeutic proteins derived from lipocalins. These proteins are naturally occurring, low-molecular-weight human proteins found in blood plasma and other bodily fluids. The company’s pipeline currently has three drug candidates in development, one of which is PRS-080, designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis. The company is also developing PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. Lastly, Pieris is also developing PRS-343, a bispecific protein for oncology diseases. The company collaborates with a wide range of larger companies to aid in the development of their product candidates, including Allergan, Inc, Sanofi Group and La Roche. For more on Pieris, visit the company’s website.

To continue reading, please Login or Join